Addition of Ublituximab to Ibrutinib Improves PFS in High-Risk CLL

[Anonymous]

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020; 18 (8): 464

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索